← Back to the library
Published

GHRP-6

A GH secretagogue (GHS-R1a agonist) that is not FDA-approved, sits in FDA Category 2 (503B), and is prohibited in sport under WADA S2.

3
Primary sources
Not staged
Evidence stage
Jul 2026
Last reviewed

This page describes where GHRP-6 has been studied, not what it will do for you. Findings here come largely from animal and cell models and do not establish safety or benefit in humans. Nothing here is medical advice, and Proven Panel sells nothing.

What it is

GHRP-6 is a growth-hormone-releasing peptide — a synthetic growth-hormone secretagogue that acts on the ghrelin/GH-secretagogue receptor (GHS-R1a) to stimulate GH release.S1

Marketed as

GHRP-6 is promoted for muscle gain, fat loss, and recovery, often alongside a GHRH analog. These are marketing claims, not established effects.S1

Regulatory status (US)

GHRP-6 is not FDA-approved for any indication.S1 On FDA's compounding framework it appears in the active Category 2 table (503B) — a designation reflecting FDA-identified risk during review, not an approval.S1

Around the world

GHRP-6 is not an approved medicine; it circulates internationally as a research chemical / research-use-only material rather than a licensed drug.S1S2

Evidence

Human therapeutic evidence is limited; GHRP-6 has been studied mainly in early or preclinical GH-axis contexts and is not an approved therapy.S1 Its marketed body-composition uses are not supported by an approved-label evidence base.S1

Anti-doping

As a GH secretagogue, GHRP-6 is prohibited at all times under WADA S2 (peptide hormones, growth factors, related substances and mimetics).S2S3

Safety

FDA's general Category 2 concerns apply: possible immunogenicity for some routes, impurity / characterization complexity, and limited human safety data.S1

What's changing

The item to track is whether GHRP-6's Category 2 status shifts after FDA's compounding decisions.S1

Sources

Every reference below is a primary source cited in this entry, drawn from the approved corpus.

  1. 01
  2. 02
  3. 03

Follow this compound

Get an email when FDA / WADA / ClinicalTrials moves on GHRP-6.

Follow this

The Panel Brief

What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.

You must be 18 or older to create an account.